<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844203</url>
  </required_header>
  <id_info>
    <org_study_id>APHP191089</org_study_id>
    <secondary_id>2019-A02976-51</secondary_id>
    <nct_id>NCT04844203</nct_id>
  </id_info>
  <brief_title>Prevalence of Orthostatic Tremor in Patients With Unsteadiness</brief_title>
  <acronym>EMG-SOT</acronym>
  <official_title>Prevalence of Orthostatic Tremor by Surface Electromyographic Recording in Patients Reporting Unsteadiness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical presentation of orthostatic tremor (OT) may be misleading and simply perceived by a&#xD;
      postural instability such as in several peripheral neuropathies. In addition, peripheral&#xD;
      neuropathies represent the leading cause of pathologies associated with OT. Among patients&#xD;
      referred for an electroneuromyogram (ENMG) for peripheral neuropathy and presenting with&#xD;
      postural unsteadiness, OT assessment will be systematically performed. Demographic, clinical&#xD;
      and polygraphy characteristics of these patients will be analyzed and prevalence of OT in the&#xD;
      general population of peripheral neuropathies will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Among patients who will be referred for ENMG and exploration of a neuropathy, orthostatic&#xD;
      tremor will be investigated systematically.&#xD;
&#xD;
      Main objective and primary endpoint:&#xD;
&#xD;
        -  To estimate the prevalence of OT with its 95% confidence interval in the population of&#xD;
           patients defined above&#xD;
&#xD;
        -  Presence of OT confirmed by surface EMG (polygraphy) in patients with standing&#xD;
           instability referred for ENMG.&#xD;
&#xD;
      Secondary objectives and end points&#xD;
&#xD;
        -  Determine the demographic, clinical, electrophysiological characteristics of patients&#xD;
           with OT; Estimate the prevalence of peripheral neuropathy in patients with OT; Duration&#xD;
           of symptoms; Correlation with quantitative neuropathy scores (ISS, MRC, ONLS, R-ODS)&#xD;
&#xD;
        -  Age, sex, clinical parameters: symptoms reported by the patient (instability, tremor,&#xD;
           weakness, pain, falls), duration, current medications, ISS score, MRC score, ONLS score,&#xD;
           R-ODS score) and electrophysiological parameters (mean frequency of OT in Hertz, MUNIX&#xD;
           score (number of motor units in the anterior tibialis, calculated by software on the&#xD;
           ENMG machine).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of orthostatic tremor (OT</measure>
    <time_frame>Day 0</time_frame>
    <description>Prevalence of OT (95% confidence interval) in patients complaining of postural instability and referred for ENMG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Neuropathy Cause and Treatment (INCAT) Sensory Sum Score (ISS) simplified</measure>
    <time_frame>Day 0</time_frame>
    <description>The ISS ranges from 0 (normal sensation) to 20 (most severe sensory deficit) and is composed of the summation of the following sensation evaluations : pinprick arm grade (range 0-4) ; vibration arm grade (range 0-4) ; pinprick leg grade (range 0-4); vibration leg grade (range 0-4): two-point discrimination grade (range 0-4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Research Council (MRC) score</measure>
    <time_frame>Day 0</time_frame>
    <description>The MRC score grades muscle power on a scale of 0 (no detectable contraction) to 5 (normal force, comparable to the healthy side)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Neuropathy Limitations Scale (ONLS) score</measure>
    <time_frame>Day 0</time_frame>
    <description>The ONLS score is be completed by adding the total of the Arm disability scale score (0-5) and Leg disability scale score (0-7) yielding a total score of 0-12 (higher score indicates higher disability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rasch-built Overall Disability Scale (R-ODS) score</measure>
    <time_frame>Day 0</time_frame>
    <description>R-ODS scale comprising 24 items evaluates the ability to perform daily activities. The answers are rated on a scale of 0 to 48 (with 0 being very poor and 48 being best performance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OT frequency</measure>
    <time_frame>Day 0</time_frame>
    <description>OT frequency in Hz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor unit number index (MUNIX)</measure>
    <time_frame>Day 0</time_frame>
    <description>MUNIX is a method for assessment of number of motor units using the compound muscle action potential (CMAP) and surface electromyographic interference pattern (SIP).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Orthostatic Tremor</condition>
  <condition>Neuropathy</condition>
  <arm_group>
    <arm_group_label>Patients with unsteadiness</arm_group_label>
    <description>Patients with unsteadiness referred for an ENMG</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Polygraphy with surface electrodes</intervention_name>
    <description>Patients referred for ENMG to the Clinical Physiology Department and complaining of postural unsteadiness will undergo a polygraphy recording using surface electrodes (Natus Medical Incorporated), performed at the end of ENMG</description>
    <arm_group_label>Patients with unsteadiness</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient referred to the Clinical physiology Department for an ENMG (investigation of&#xD;
        the neuropathy)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  All patients complaining of instability when standing up and referred for an ENMG&#xD;
&#xD;
          -  Patient informed and having expressed his non-opposition to participating in the&#xD;
             research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient's refusal to participate in the study&#xD;
&#xD;
          -  Impossibility to stand&#xD;
&#xD;
          -  No affiliation to health insurance&#xD;
&#xD;
          -  Patients under a legal protection measure or unable to express their will&#xD;
&#xD;
          -  Patient under the State Medical Assistance (AME)&#xD;
&#xD;
          -  Patient under 18 years old&#xD;
&#xD;
          -  Pregnant women, parturients and breast-feeding mothers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Nathalie KUBIS, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP, Lariboisière Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie KUBIS, MD, PhD</last_name>
    <phone>+33149958108</phone>
    <email>nathalie.kubis@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pierre LOZERON, MD, PhD</last_name>
    <phone>+33149958076</phone>
    <email>pierre.lozeron@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>APHP Lariboisière Hospital, Clinical Physiology Department</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nathalie KUBIS, MD, PhD</last_name>
      <phone>+33149958108</phone>
      <email>nathalie.kubis@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pierre LOZERON, MD, PhD</last_name>
      <phone>+33149958076</phone>
      <email>pierre.lozeron@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electroneuromyography</keyword>
  <keyword>Polygraphy</keyword>
  <keyword>Unsteadiness</keyword>
  <keyword>Tremor</keyword>
  <keyword>Anti-MAG neuropathy</keyword>
  <keyword>Chronic demyelinating inflammatory neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

